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be a viable therapeutic route?
Alison Powella, Bruce Catersona, Clare Hughesa, Alison Paulb, Craig Jamesb, Stephen Hopkinsb, Omar Mansourc and
Peter Griffithsc
aSchool of Biosciences, Cardiff University, Cardiff, UK; bSchool of Chemistry, Cardiff University, Cardiff, UK; cDepartment of Pharmaceutical,
Chemical and Environmental Sciences, Faculty of Engineering and Science, University of Greenwich, Kent, UK
ABSTRACT
The ability of a polymer therapeutic to access the appropriate subcellular location is crucial to its efficacy
and is defined to a large part by the many and complex cellular biological and biochemical barriers such
that a construct must traverse. It is shown here that model dextrin conjugates are able to pass through a
cartilaginous extracellular matrix into chondrocytes, with little perturbation of the matrix structure, indicat-
ing that targeting of potential therapeutics through a cartilaginous extracellular matrix should be proven
possible. Rapid chondrocytic targeting of drugs which require intra cellularisation for their activity and uni-
form extracellular concentrations of drugs with an extracellular target, is thus enabled though polymer
conjugation.
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Introduction
Articular cartilage lines the load bearing joints of the body acting
to reduce friction and absorb mechanical loads. It is an aneural,
avascular, hypocellular tissue, composed of a dense extracellular
matrix controlled and secreted by the chondrocytes within it. The
chondrocytes comprise less than 2% of the volume of mature
articular cartilage with the remainder comprising a highly organ-
ised network of collagen fibrils, proteoglycans and water. The
matrix macromolecules of articular cartilage give the tissue its
unique structure and function. These structural macromolecules
include collagens (mainly type II), proteoglycans and non-
collagenous proteins. The type II collagen fibril meshwork gives
the cartilage its form and tensile strength. The proteoglycans and
non-collagenous proteins of articular cartilage bind to the collagen
meshwork or become mechanically entrapped within it. The major
proteoglycan of articular cartilage is aggrecan, which has numer-
ous glycosaminoglycan chains attached to its core protein and
forms huge multimolecular aggregates with hyaluronan and a link
protein. Hydration of the glycosaminoglycan chains of aggrecan
provides cartilage with its compressibility functions.
More than ten million people in the UK have long-term health
problems due to arthritis or a related condition [1]. The most com-
mon arthritic diseases are osteoarthritis and rheumatoid arthritis,
both of which involve erosion of the cartilage cushioning the ends
of bones within the joint. Symptoms include joint-pain and stiff-
ness, which can lead to disability. Cartilage degeneration in arth-
ritis is ultimately due to the enzymatic degradation of the
cartilage extracellular matrix. The complexity and density of the
cartilage extracellular matrix results in a barrier to the passage of
molecules through the matrix, however its maintenance is crucial
for tissue function. In the synovial joint the articular surface
is lubricated and nourished by synovial fluid, a filtrate of
blood plasma containing high levels of the glycosaminoglycan
hyaluronan and the proteoglycan lubricin (SZP) [2]. The relative
viscosity of synovial fluid provides an additional barrier for the dif-
fusion of molecules into chondrocytes.
Current therapies for arthritis mainly treat the clinical disease
symptoms rather than targeting the degradative enzymes
themselves. Treatments such as steroidal and non-steroidal anti-
inflammatory drugs are still the mainstay of treatment [3,4] and
can have adverse side effects including high blood pressure [5–7],
osteoporosis [8], cataracts [9,10] and gastrointestinal bleeding [11].
The newly released anti- tumour necrosis factor (TNF) drugs
(Etanercept, infliximab and adalimumab) which block the pro-
inflammatory cytokine TNF in rheumatoid and psoriatic arthritis
[12,13] are efficacious for only a small cohort of patients and are
only prescribed for UK patients with severe and crippling forms of
the disease as they carry the risk of serious side effects due to
immuno-suppression [14].
In recent years, a number of compounds have been identified,
in in vitro studies, that are able to inhibit the initial loss of the extra-
cellular matrix component aggrecan, via often unknown mechanis-
tic inhibition of the proteases ADAMTS-4 and/or -5. These
compounds have notably included the neutraceutical glucosamine
[14–16] and the sulphated sugar derivative pentosan polysulphate
[17,18]. In addition, the physiological inhibitor of ADAMTS-4 and -5,
TIMP-3, has been shown to ablate the initial loss of aggrecan in
cytokine induced degradative mechanisms [19].
The idea of water-soluble polymers functioning as carriers of
drugs through conjugation via a biodegradable spacer and/or
linker could facilitate targeted drug release was first put forward
in the mid-1970s [20]. The last two decades have seen successful
clinical application of polymer conjugates to target therapeutic
agents for the treatment of a range of diseases including age
related macular degeneration, cancer and liver disease [21–24].
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These therapeutic conjugates have utilised a number of polymers
as drug delivery vehicles including N-(2-hydroxypropyl) methacry-
lamide (HPMA) [25,26], poly(ethylene glycol) (PEG) [27–29] and
dextrin [30,31]. Conjugation of drugs to polymers has allowed for
specific targeting of the therapeutic activity of a drug to the dis-
eased tissue. This results in a reduction of the dose required for
efficacy of treatment and in potential toxicity of the drugs,
respectively.
Expanding this modality to the treatment of arthritic joints,
requires that such polymers in order to deliver their drug payload
must be able to pass through a cartilaginous extracellular matrix
rich in negatively charged proteoglycans, either to reach their chon-
drocytic targets or to achieve even distribution throughout the car-
tilage extracellular matrix. In the selection of suitable targeting
polymers and polymer conjugates for the treatment of arthritic dis-
ease, quantifying whether these compounds can indeed pass
through the barriers presented by the synovial joint without induc-
ing their disruption will be of vital importance. Of the potential bar-
riers present we believe that the interactions of polymers and
polymer conjugates with proteoglycans, within the cartilage extra-
cellular matrix as well as coating its surface, will be the most influ-
ential on their movement. This study focussed on investigating the
interactions of polymers and polymer conjugates with the cartilage
proteoglycans aggrecan, lubricin and synovial fluid.
Materials and methods
Preparation of synovial fluid samples
Synovial fluid samples were harvested from the metacarpo/meta-
tarso phalangeal joints of 18 month old cows legs using a 15
gauge needle.
Preparation of lubricin
Following effusion of the synovial fluid from the joints of 18 month
old cows legs as described above the joints were lavaged using
1.6M sodium chloride to isolate the lubricin coating the surface of
the articular cartilage [32].
Preparation of aggrecan aggregates
Bovine articular cartilage explants were established using previous
methodologies [33]. Following a 48 h preculture explants were
washed into serum free DMEM. The explants were then cultured
in either (i) serum free DMEM or (ii) serum free DMEMþ IL-1a
(10 ng/ml). Cultures were incubated for up to 96 h; media and
explants were harvested and finely diced prior to addition of
guanidine extraction buffer (4M guanidine HCl, 50mM sodium
acetate of pH 5.8–6.8, 0.1M 6-amino-hexanoic acid, 5mM benza-
midine HCl, 10mM ethylene diamine tetra acetic acid (EDTA, tetra-
sodium salt), 1mM phenyl methyl sulphonyl fluoride (PMSF-10ml
per gram cartilage wet weight)and incubated for 48 h at 4 C with
constant agitation. The extracted cartilage debris was removed by
centrifugation at 15,000 rpm for 10min and discarded. The liquid
supernatant was then dialysed exhaustively against MilliQTM water.
The density of the extract was adjusted to 1.5 g/ml by addition of
CaCl2 and aggrecan-hyaluronan aggregate purified by ultracentri-
fugation in a Beckman L-60 Ultracentrifuge at 37,000 rpm for 70 h
at 4 C. The extract was fractionated into four equal pools desig-
nated A1–A4, the lowest fraction A1 contained the purified aggre-
can-hyaluronan complex with a density>1.57 g/ml.
Analysis of cellular uptake of polymer conjugates by FACS and
fluorescence microscopy
Explants were harvested and pre-cultured using previously estab-
lished methods prior to incubation in the presence or absence of
IL-1a (10 ng/ml) for 96 h [34,35]. Cultures were then incubated in
DMEM with 50 lg/ml gentamicin and 10% (v/v) heat inactivated
FBS in the presence or absence of Oregon Green labelled poly-
mers at a range of concentrations (1–10 lg/ml) for a number of
time points (2–24 h). Following incubation with polymers explants
were either washed in phosphate buffered saline and viewed
using a confocal microscope or digested to free the cells using
Pronase (1% (w/v) in DMEM containing 50lg/ml gentamicin and
10% (v/v) heat inactivated FBS) for 30min at 37 C, followed by
collagenase type II (0.4% (w/v) in DMEM containing 50lg/ml gen-
tamicin and 10% (v/v) heat inactivated FBS) for 45min at 37 C.
The isolated cells was pelleted by centrifugation resuspended in
PBS and run on a FACsCanto (BD Biosciences, San Jose, CA).
Pulsed-gradient spin-echo nuclear magnetic resonance
Measurements on the purified freeze-dried aggrecan-hyaluronan
complex re-dispersed in D2O were conducted on a Bruker AMX360
NMR spectrometer using a stimulated echo-sequence [35]. This
configuration used either a 5mm (Cryomagnet Systems, IL) or
10mm (Bruker) diffusion probe in conjunction with Bruker or
Woodward gradient spectroscopy accessories.
The self-diffusion coefficient Ds was extracted by fitting to
Equation (1) either by (i) the integrals for a given peak or (ii) the
individual frequency channels present in the entire band shape via
component resolved (CORE) analysis [36];
Aðd;G;DÞ ¼ Aoexp½kDs (1)
where A is the signal amplitude in the absence (Ao) and pres-
ence of the field gradient pulses A d;G;Dð Þ) and k ¼
c2G2 30D dþrð Þ2 10d3þ30rd2þ35d2rþ14r3ð Þ
2
30
 
given that c is the magne-
togyric ratio, D the diffusion time, r the gradient ramp time, d the
gradient pulse length and G the gradient field strength.
Small-angle neutron scattering
SANS experiments were performed on the LOQ diffractometer
based at the spallation source at the Rutherford Appleton
Laboratory, UK, where a Q range of 0.007 to 0.3 Å1 is accessible
using 2< k< 10Å, where Q¼ (4p/k)sin(h/2)Q ¼ 4pk
 
sin h2
 
.
Samples were contained in 1mm pathlength,
UV-spectrophotometer grade, quartz cuvettes (Hellma) and
mounted in aluminium holders on top of an enclosed, computer-
controlled, sample chamber. Temperature control was achieved
through the use of a thermostatted circulating bath pumping fluid
through the base of the sample chamber. Under these conditions
a temperature stability of better than ±0.5 C can be achieved.
Experimental measuring times were approximately 40–60min.
All scattering data were normalised for the sample transmission
and the incident wavelength distribution was corrected for instru-
mental and sample backgrounds using a quartz cell filled with
either H2O or D2O (this also removes the incoherent instrumental
background arising from vacuum windows, etc.) and corrected for
the linearity and efficiency of the detector response using the
instrument specific software package (e.g. Mantid). The data were
put onto an absolute scale using a well-characterised partially deu-
terated polystyrene blend standard sample.
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The intensity of the scattered radiation, I(Q), as a function of
the wavevector, is given by:
I Qð Þ ¼ NV2 Dqð Þ2P Qð ÞS Qð Þ þ Binc (2)
where P(Q) describes the morphology of the scattering species,
S(Q) describes the spatial arrangement of the species in solution,
N is the number of species per unit volume, V is the volume of
the species, Dq is the difference in the neutron scattering length
density (SLD) of the scatterer and the solvent and Binc is the inco-
herent background scattering.
Results and discussion
Pulsed gradient spin echo nuclear-magnetic resonance spectros-
copy( PGSE-NMR) provides a convenient and non-invasive chem-
ically selective technique for measuring translational motion and
in particular the self-, rather than mutual-diffusion coefficient.
Therefore, PGSE-NMR can be used both to quantify the mobility of
molecules and to assess the impact of the presence of the mole-
cules on the extracellular matrix components themselves. The dif-
fusion of small solutes (including water and Naþ) has been shown
to be impeded by up to 40% by the presence of an extracellular
matrix, implying that the movement of larger molecules such as
polymers may be very significantly affected by the presence of a
matrix [37].
A vital component in the selection of polymer-drug conjugates
for the treatment of arthritic disease is the selection of either poly-
mers which are able to target a drug with intracellular activity and
its ability to diffuse rapidly through the extracellular matrix into
the chondrocyte. Accordingly, the rate of diffusion of dextrin poly-
mers (as model conjugates) has been quantified both in free solu-
tion and through components of the cartilaginous extracellular
matrix (Figure 1). The matrix comprises an aggrecan-hyaluronan
aggregate gel purified by density gradient centrifugation from
bovine articular cartilage, is presented in Table 1. For the
Mw¼ 10 kgmol1 dextrin sample, the self-diffusion coefficient was
slowed from Ds¼ 2.7 x 1010 m2s1 in free solution, corresponding
to a hydrodynamic radius of a few nanometres, to Ds¼ 2.6 x 1011
m2s1 in the aggrecan-hyaluronan gel (Table 1). The higher
molecular weight dextrin shows a larger reduction, though the
free solution retardation is consistent with the increase in molecu-
lar weight of a random coil configuration. By drawing analogies of
the diffusion of such a polymer in related (mucin) gels, this signifi-
cant retardation is probably not a consequence of direct associ-
ation of the dextrin with the aggrecan-hyaluronan aggregate, but
rather steric hindrance due to the presence of the highly
entangled matrix of the aggrecan-hyaluronan aggregate [38]. The
non-linearity of the attenuation function clearly demonstrates the
presence of more than a single diffusion rate and the CORE ana-
lysis identifies these to be dextrin (the initial decay) and the
underlying much slower (two orders of magnitude slower) diffu-
sion of the aggrecan-hyaluronan aggregates.
On the other side, we can also comment on the effect of succi-
noylation, which is the first step in dextrin functionalisation – on
the conformation of the polymer, as characterised by their self-dif-
fusion coefficients (Figure 2). The self-diffusion coefficient drops
smoothly (increasing hydrodynamic size) with increasing mole
Figure 1. Experimental two-dimensional PGSE NMR dataset (left) and analysis of peak integrals used to extract the rates of diffusion (right) for
Mw¼ 10 kgmol1dextrin in free solution and in an aggrecan-hyluronan gel, the open symbols correspond to the attenuation function for the peak at 3 ppm in the
spectrum from 10mg/ml (1wt%) dextrin in solution i.e. the raw data presented above. The filled symbols correspond to two superimposed datasets, necessary to span
the wide dynamics range present in these systems, again for the 3 ppm peak, arising from the spectrum of 10mg/ml (1wt%) dextrin in an aggrecan-hyaluronan gel
(20mg/ml GAG).
Table 1. Self-diffusion coefficients in free solution (concentration 1wt%) and
aggrecan-hyaluronan gels measured by PGSE-NMR and the retardation ratio
from free solution to gel.
Sample Free solution Aggrecan-hyaluronan Ratio
Mw¼ 10 kgmol1 2.7 1010 m2s1 2.6 1011 m2s1 10
Mw¼ 51 kgmol1 1.0 1010 m2s1 5.0 1012 m2s1 20
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percent of succinoylation, up to a value of around 10mol%,
above which the self-diffusion coefficient becomes largely constant
at 1 10 10m2s1, consistent with an hydrodynamic radius of
around 50Å.
The (gel) structure of cartilage extract and various derivative
materials have been examined based on Beaucage model by
small-angle neutron scattering (SANS) in the absence and pres-
ence of added dextrin, as shown in Figure 3(a,b) (representative
data only presented). In the case of the 18m direct cartilage
extract, where the scattering from the gel itself is significant
(I(Q)> 10 cm1 at Q< 0.01 Å) and dominates the mixture scatter-
ing (for dextrin, I(Q)< 0.5 cm1 at Q< 0.01 Å), addition of the two
dextrin samples induced no noticeable perturbation in the scat-
tering and hence, structure of the direct cartilage extract gel. In
the case of the IL-1 systems and various other derivative materi-
als (data not presented, Figure 3(b)), the same conclusion may
be drawn, but not so directly. It is obvious that the scattering
does vary across the different mixed systems, but it is shown
below that this is a consequence of the weaker and comparable
intensities of the various components rather than one dominat-
ing contribution, as in the case of the 18m direct cartilage
extract.
A number of strategies exist for interpreting SANS data. The
simplest is to consider the slope of the data when plotted on a
double logarithmic representation, extracting the so-called Q
dependency, I(Q)/Qn, illustrating the most probable shape of
the scatterer; n¼ 1 indicates a rod, n¼ 2 a flat structure, increasing
all the way to n¼ 4 for a large, solid object. For systems like gels,
one might anticipate n¼ 5/3 to the n¼ 3, reflecting a transition
from a mass to volume fractal character associated with the differ-
ing length-scales present in the gel. This is indeed the case.
Alternatively, one may numerically analyse the data in terms of
specific models, based on some a priori knowledge of the likely
conformation or arrangement of molecules in solution. For dextrin,
a simple polydisperse Gaussian coil model adequately describes
the data for Mw¼ 51 kgmol1 dextrin sample, with RG¼ 80 Å
(consistent with the theoretical prediction for the ratio of the
radius of gyration and hydrodynamic radius, RG/RH¼ 1.5).
For the gels, an appropriate treatment is the Shibayama-
Geissler two-length scale model [39,40] which treats the scattering
as the additional of two components, with fraction f;
I Qð Þ ¼ fIð0Þ1
1
1þ Dþ13
 
Q2a21
 D=2 þ 1 fð ÞI 0ð Þ2exp Q2a22 þ B
(3)
where D is the scaling exponent and a22 R
2
G
3 . The parameters
describing the Shibayama-Geissler fit to these data are presented
in Table 2. By and large, the fitting is most sensitive to the
Lorentzian component embodied in the scaling exponent D, with
a length scale ða21Þ of around 100Å, but the 18m direct cartilage
extract also requires a Guinier term, with length scale slightly
shorter. Most importantly, as is evident from the raw data where
subtle differences are only observed at higher Q values, the
parameters are largely insensitive to the addition of the dextrin i.e.
it may be considered to be non-perturbing.
Having shown it is possible for dextrin to diffuse through
the gel whilst having little impact on its structure, the progres-
sion of (Oregon Green labelled) dextrin into chondrocytes was
assessed. Each of the cultures was incubated in dextrin-Oregon
Green at 1, 5 and 10 lg/ml for 2–24 h, respectively. Cells were
released from monolayer cultures by gentle trypsinisation and
by rapid pronase and collagenase digest from explant and ex
vivo transwell grafts cultures. FACS analysis of these cell popula-
tions with 10 mg/ml dextrin-Oregon Green at 2, 4, 8 and 24 h
are shown in Figure 4.
Cellular uptake of the dextrin conjugate achieved in the pres-
ence of a cartilaginous extracellular matrix in both explant cultures
and in ex vivo transwell grafts is shown in Figure 4(a,b), respect-
ively. In cartilage explants cellular uptake was achieved in over
90% of cells following 8 h exposure (Figure 4(b)). Uptake of dex-
trin-Oregon Green was slower in ex vivo transwell grafts than in
explants cultures with only 66% of cells containing the
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Figure 2. Self-diffusion coefficients in free solution as a function of degree of succinoylation measured by PGSE-NMR for dextrin Mw¼ 51 kgmol1at 1wt% polymer.
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fluorophore following 24 h exposure (Figure 4(a)). In the ex vivo
transwell grafts the dextrin-Oregon Green was only added to the
insert medium to mimic the situation in vivo where a therapeutic
agent injected into the joint would only be able to penetrate the
cartilage at the articular surface (Figure 5). This restricted access to
one surface explains the apparently slower rate of uptake by chon-
drocytes within the ex vivo transwell grafts compared to chondro-
cytes within cartilage explants (Figure 4(a,b)).
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Figure 3. (a) Small-angle neutron scattering from 1mm thick (H2O) aqueous solutions of direct cartilage extract from 18month old knee joints in the absence of dex-
trin and in the presence of 1wt% dextrin, Mw¼ 10 and 51 kgmol1, respectively. The lines of best fit have been derived from the analysis using the Beaucage model
as described in the text. Also shown for comparison is the scattering from 1wt% Mw¼ 51 kgmol1 dextrin (in D2O). The lines of best fit for this dextrin sample has
been derived from a simple Gaussian coil model, RG¼ 80 (± 3) Å. (b) Small-angle neutron scattering from 2mm thick (D2O) reconstituted aqueous solutions of IL-1 in
the absence of dextrin and in the presence of 1wt% dextrin Mw¼ 51 kgmol1. The lines of best fit have been derived from the analysis using the gel plus coil model
as described in the text. Also shown for comparison is the scattering from the dextrin solution.
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In order to determine whether dextrin-Oregon Green was able
to pass right through a cartilaginous extracellular matrix it was
only added to the insert medium of the ex vivo transwell grafts
and both the insert and outer medium were analysed for its pres-
ence using fluorescence spectroscopy following a number of dif-
ferent incubation times (Figure 6). It is tacitly assumed, as shown
in other studies, that the Oregon Green remains attached to the
dextrin [41].
Table 2. Parameters derived from an analysis of the scattering data in terms of the Shibayama-Geissler two-length scale model.
Sample Guinier scale Lorentzian scale Radius of gyration(Å) Fractal dimension Correlation length(Å)
18m 0.2 18 85 ((þ/ 3) 2.2 ((þ/ 0.1) 235 ((þ/ 30)
18m plus dextrin 10 kgmol1 n/a 18 n/a 2.3 140
18m plus dextrin 51 kgmol1 n/a 14 n/a 2.3 135
IL-1 n/a 0.2 n/a 2.2 105
IL-1 plus dextrin 51 kgmol1 0.3 1.1 55 2.2 90
Figure 4. FACS analysis of dextrin-Oregon Green uptake with time in: (a) chondrocytes isolated from ex vivo transwell grafts following exposure to dextrin-Oregon
Green and (b) chondrocytes isolated from articular cartilage explants cultures following exposure to dextrin-Oregon Green.
Insert starting medium
Outer
Medium
Cartilage matrix plug
Figure 5. Picture of ex vivo transwell grafts and diagrammatic representation of
the structure of the cultures (insert).
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Figure 6. Analysis of the distribution of fluorescence in transwell filter cultures by
fluorescence spectroscopy.
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The dextrin-Oregon Green was able to pass right through the
extracellular matrix of the ex vivo transwell grafts and was
detected in the outer medium of the cultures following only 2 h of
incubation with the conjugate (Figure 6). Following 24 h incuba-
tion on the filter insert cultures over 13% of the total fluorescence
present in the cultures was detected in the outer medium
(Figure 6).
Conclusions
Combined, the data presented here demonstrate that dextrin is
able to successfully diffuse through a cartilaginous extracellular
matrix and into the chondrocytes within, inducing little perturb-
ation in that matrix, thus indicating the feasibility of drug delivery
using polymer conjugates for the treatment of arthritis.
Disclosure statement
None of the authors has received any financial interest or benefit
that has arisen from the direct applications of our research.
Funding
This work was supported by Engineering and Physical Sciences
Research Council under Platform Grant (EP/C013220/1)
“Bioresponsive polymer therapeutics; synthesis and characterisa-
tion of novel nanomedicines”.
References
[1] Working with Arthritis, Arthritis Research UK, June 2016.
Available from: http://www.arthritisresearchuk.org/policy-
and-public-affairs/reports-and-resources/reports/work-report.
aspx.
[2] Rhee DK, Marcelino J, Baker M, et al. The secreted glycopro-
tein lubricin protects cartilage surfaces and inhibits synovial
cell overgrowth. J Clin Invest. 2005;115:622–631.
[3] Marini S, Fasciglione GF, Monteleone G, et al. A correlation
between knee cartilage degradation observed by arthros-
copy and synovial proteinases activities. Clin Biochem.
2003;36:295–304.
[4] Brandt KD, Slowman-Kovacs S. Nonsteroidal anti-inflamma-
tory drugs in treatment of osteoarthritis. Clin Orthop.
1986;213:84–91.
[5] Gabriel SE, Wagner JL. Costs and effectiveness of nonsteroi-
dal anti-inflammatory drugs: the importance of reducing
side effects. Arthritis Care Res. 1997;10:56–63.
[6] Hammer F, Stewart PM. Cortisol metabolism in hyperten-
sion. Best Pract Res Clin Endocrinol Metab. 2006;20:
337–353.
[7] Reiche ML. Complications of intravitreal steroid injections.
Clin Care. 2005;76:450–460.
[8] Ledford D, Apter A, Brenner AM, et al. Osteoporosis in the
corticosteroid treated patient with asthma. J Allergy Clin
Immunol. 1998;102:353–363.
[9] Moore P. Inhaled corticosteroids increase cataract risk.
Lancet. 1997;350:120.
[10] Urban RC, Cotlier E. Corticosteroid-induced cataracts. Surv
Ophthalmol. 1986;31:102–110.
[11] Tringham VM, Cochrane P. Aspirin, paracetamol, diflunisal,
and gastrointestinal blood-loss. Lancet. 1979;1:1409.
[12] Punzi L, Podswiadek M, Sfriso P, et al. Pathogenic and clin-
ical rationale for TNF-blocking therapy in psoriatic arthritis.
Autoimmun Rev. 2007;6:524–528.
[13] Berthelot J-M, Varin S, Cormier G, et al. 25mg etanercept
once weekly in rheumatoid arthritis and spondylarthrop-
athy. Joint Bone Spine. 2007;74:144–147.
[14] Maillard H, Ornetti P, Grimault L, et al. Severe pyogenic
infections in patients taking infliximab: a regional cohort
study. Joint Bone Spine. 2005;72:330–334.
[15] Largo R, Alvarez-Soria MA, Diez-Ortego I, et al. Glucosamine
inhibits IL-1beta-induced NFkappaB activation in human
osteoarthritic chondrocytes. Osteoarthritis Cartilage.
2003;11:290–298.
[16] Ilic MZ, Martinac B, Handley CJ. Effects of long-term expos-
ure to glucosamine and mannosamine on aggrecan degrad-
ation in articulat cartilage. Osteoarthritis Cartilage.
2003;11:1–10.
[17] Smith JG, Hannon RL, Brunnberg L, et al. A multicentre clin-
ical study of the efficacy of sodium pentosan
polysulphate and carprofen in canine osteoarthritis. Norsk
Veterinaertidsskrift. 2002;123–130.
[18] Rogachefsky RA, Dean DD, Howell DS, et al. Treatment
of canine osteoarthritis with sodium pentosan
polysulphate and insulin-like growth factor-1. Ann N Y Acad
Sci.1994;732:392–394.
[19] Gendron C, Kashiwagi M, Hughes CE, et al. TIMP-3 inhibits
aggrecanases-mediated glycosaminoglycan release from
cartilage explants stimulated by catabolic factors. FEBS
Letters. 2003;555:431–436.
[20] Vasey PA, Kaye SB, Morrison R, et al. Phase I Clinical and
pharmacokinetic study of PK1 [N-(2-hydroxypropyl) metha-
crylamide copolymer doxorubicin]: first member of a new
class of chemotherapeutic agents- drug-polymer conju-
gates. Clin Cancer Res. 1999;5:83–94.
[21] Duncan R. Targeting and intracellular delivery of drugs. In:
Meyers RA, editor. Encyclopedia of molecular cell biology
and molecular medicine. Weinheim, Germany: Wiley-VCH,
Verlag, GmbH & Co; 2005. p.163–204.
[22] Duncan R. Polymer conjugates as anticancer nanomedi-
cines. Nat Rev Cancer. 2006;6:688–701.
[23] Duncan R, Ringsdorf H, Satchi-Fainaro R. Polymer therapeu-
tics , polymers as drugs, conjugates and gene delivery sys-
tems: past, present and future opportunities. Adv Polym Sci.
2006;192:1–8.
[24] Yasukawa T, Ogura Y, Sakurai E, et al. Intraocular sustained
drug delivery using implantable polymeric devices. Adv
Drug Deliv Rev. 2005;57:2033–2046.
[25] Duncan R, Vicent MJ, Greco F, et al. Polymer-drug conju-
gates: towards a novel approach for the treatment of endo-
crine-related cancer. Endocr Relat Cancer. 2005;12:189–199.
[26] Nan A, Nanayakkara NPD, Walker LA, et al. N-(2-hydroxypro-
pyl)methacrylamide (HPMA) copolymers for targeted deliv-
ery of 8-aminoquinoline antileishmanial drugs. J Control
Release. 2001;77:233–243.
[27] Ould-Ouali L, Noppe M, Langlois X, et al. Self-assembling
PEG-q(CL-co-TMC) copolymers for oral delivery of poorly
water soluble drugs: a case study with risperidone.
J Control Release. 2005;102:657–668.
[28] Cheng J, Teply BA, Sherifi I, et al. Formulation of functional-
ized PLGA-PEG nanoparticles for in vivo targeted drug
delivery. Biomaterials. 2007;28:869–876.
[29] Yu D, Peng P, Dharap SS, et al. Antitumor activity of poly(-
ethylene glycol)-camptothecin conjugate: The inhibition of
tumor growth in vivo. J Control Release. 2005;110:90–102.
JOURNAL OF DRUG TARGETING 925
[30] Hreczuk-Hirst D, Chicco D, German L, et al. Dextrins as
potential carriers for drug targeting: tailored rates of dextrin
degradation by introduction of pendant group. Int J Pharm.
2001;230:57–66.
[31] Hreczuk-Hirst D, German L, Duncan R. Dextrins as carriers
for drug targeting: reproducible succinoylation as a means
to introduce pendant groups. J Bioact Compat Polym. 2001;
16:353–364.
[32] Jones ARC, Gleghorn JP, Hughes CE, et al. Binding and
localization of recombinant lubricin to articular cartilage
surfaces. J Orthop Res. 2007;25:283–292.
[33] Hughes CE, Caterson B, Fosang AJ, et al. Monoclonal anti-
bodies that specifically recognise neoepitope sequences
generated by aggrecanases and matrix metalloproteinase
cleavage of aggrecan: application to catabolism in situ and
in vitro. Biochem J. 1995;305:799–804.
[34] Arner EC, Hughes CE, Decicco CP, et al. Cytokine-induced
cartilage proteoglycan degradation is mediated by aggreca-
nase. Osteoarthritis Cartilage. 1998;6:214–228.
[35] Davies JA, Griffiths PC. A phenomenological approach to
separating the effects of obstruction and binding for
the diffusion of small molecules in polymer solutions.
Macromolecules. 2003;36:950.
[36] Stilbs P, Paulsen K, Griffiths PC. Global least-squares analysis
of large, correlated spectral data sets: application to compo-
nent-resolved FT-PGSE NMR spectroscopy. J Phys Chem.
1996;100:8180–8189.
[37] Burstein D, Gray ML, Hartman AL, et al. Diffusion of small
solutes in cartilage as measured by nuclear magnetic reson-
ance (NMR) spectroscopy and imaging. J Orthop Res.
1993;11:465–478.
[38] Griffiths PC, Occhipinti P, Gumbleton M, et al. PGSE-NMR
and SANS Studies of the interaction of model polymer ther-
apeutics with mucin. Biomacromolecules. 2010;11:120–125.
[39] Shibayama M, Toyoichi T, Han CC. Small angle neutron scat-
tering study on poly(N-isopropyl acrylamide) gels near their
volume-phase transition temperature. J Chem Phys. 1992;
97:6829–6841.
[40] Mallam S, Horkay F, Hecht AM, et al. Microscopic
and macroscopic thermodynamic observations in
swollen poly(dimethylsiloxane) networks. Macromolecules.
1991;24:543.
[41] Richardson SC, Wallom KL, Ferguson EL, et al. The use of
fluorescence microscopy to define polymer localisation to
the late endocytic compartments in cells that are targets
for drug delivery. J Control Release. 2008;127:1–11.
926 A. POWELL ET AL.
